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Abstract
Background: Both Kaposi’s sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) are members of the human
gamma herpesvirus family: each is associated with various human cancers. The majority of AIDS-associated primary effusion
lymphoma (PEL) are co-infected with both KSHV and EBV. Dually-infected PELs selectively switch from latency to lytic
replication of either KSHV or EBV in response to chemical stimuli. KSHV replication and transcription activator (K-RTA) is
necessary and sufficient for the switch from KSHV latency to lytic replication, while EBV BZLF1 gene product (EBV-Z) is a
critical initiator for induction of EBV lytic replication.
Methodology/Principal Findings: We show K-RTA and EBV-Z are co-localized and physically interact with each other in
dually-infected PELs. K-RTA inhibits the EBV lytic replication by nullifying EBV-Z-mediated EBV lytic gene activation. EBV-Z
inhibits KSHV lytic gene expression by blocking K-RTA-mediated transactivations. The physical interaction between K-RTA
and EBV-Z are required for the mutual inhibition of the two molecules. The leucine heptapeptide repeat (LR) region in K-RTA
and leucine zipper region in EBV-Z are involved in the physical interactions of the two molecules. Finally, initiation of KSHV
lytic gene expression is correlated with the reduction of EBV lytic gene expression in the same PEL cells.
Conclusions/Significance: In this report, how the two viruses interact with each other in dually infected PELs is addressed.
Our data may provide a possible mechanism for maintaining viral latency and for selective lytic replication in dually infected
PELs, i.e., through mutual inhibition of two critical lytic replication initiators. Our data about putative interactions between
EBV and KSHV would be applicable to the majority of AIDS-associated PELs and may be relevant to the pathogenesis of
PELs.
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Introduction
Epstein-Barr virus (EBV) and Kaposi sarcoma (KS)-associated
herpesvirus (KSHV), also called human herpesvirus 8 (HHV-8),
are the two gamma herpesviruses currently identified in humans.
EBV infection has been associated with the development of
Buikitts’ lymphoma (BL), Hodgkin’s disease, nasopharyngeal
carcinoma and others [1–5]. KSHV is believed to be the
etiological agent of KS [6–8], and is implicated in the pathogenesis
of AIDS-associated primary effusion lymphoma (PEL), also called
body cavity-based lymphoma (BCBL), and multicentric Castle-
man’s disease [6,9,10].
Like other herpesviruses, both EBV and KSHV have latency
and lytic replication in their life cycles. The switch from latency to
lytic gene expression in KSHV requires the expression of KSHV
replication and transcription activator (K-RTA, also called RTA
or ORF50). K-RTA is apparently necessary and sufficient for the
switch from KSHV latency to lytic replication [9,10]. K-RTA is a
sequence-specific DNA-binding protein that regulates gene
expression through K-RTA-responsive elements in the transcrip-
tional regulatory regions of different subsequently expressed viral
genes [11–18]. K-RTA also interacts with other factors to
modulate its transcription potential, and some interactions are
ctritical for K-RTA-mediated switch from latency to lytic
replication [19–24].
Beyond functioning in initiating viral lytic replication, K-RTA is
involved in the induction of cellular IL-6 [25]. K-RTA also blocks
p53-mediated apoptosis by competing for binding to CBP [26]. K-
RTA might play a role in latency establishment [27,28]. K-RTA
has been shown to enhance CD21 expression, and facilitate EBV
infection because CD21 is EBV receptor in B cells [29].
EBV lytic replication can be initiated by expression of the EBV
BZLF1 gene product (EBV-Z; also referred as BZLF1, Zta, Z,
ZEBRA, and EB1) [30,31]. EBV-Z is a member of the basic
leucine zipper (bZIP) family of DNA binding proteins and has a
PLoS ONE | www.plosone.org 1 February 2008 | Volume 3 | Issue 2 | e1569sequence similar to C/EBP, c-Jun, and c-Fos [32]. EBV-Z binds
specifically to DNA with multiple specific recognition sequences
and activates transcription of both viral and cellular genes [33–
36]. One important viral gene target of EBV-Z is EBV BRLF1
gene product, E-RTA (also called BRLF1, RTA, R). K-RTA and
E-RTA are homologues genes and this family of genes is highly
conserved among gamma herpesviruses. E-RTA is coordinately
expressed as a bicistronic RNA transcript with EBV-Z [37]. E-
RTA and EBV-Z function synergistically at some promoters and
are required for the completion of the EBV lytic replication cycle
[38].
EBV-Z has additional activities other than initiation of EBV
lytic replication. These include the ability to block cell cycle
progression [39,40] and the disruption of the PML-associated
nuclear domain 10 (ND10/PODs) [41,42]. EBV-Z can also
upregulate its own expression, a property called autoregulation
[43,44]. Of note K-RTA also auto-regulates its own expression
[14,45].
PELs are B-cell non-Hodgkin’s lymphomas and most frequent-
ly occur in HIV-positive individuals as lymphomatous effusions in
the serous cavities without a detectable solid tumor mass. In the
setting of AIDS, the clinical course for most of these lymphomas
is extremely aggressive, with a mean survival from diagnosis of 5–
7 months [46]. While PELs are almost universally KSHV-
positive, the majority of PELs have concomitant EBV infection
[6,10,47].
In order to understand viral contributions to the pathogenesis of
PEL, it is important to address how EBV and KSHV interact with
each other and affect biological properties of the cell and the
viruses. There are apparent interactions between the two viruses in
PELs. EBV enhances the tumorigenecity of the dually-infected
PELs in SCID mice [48]. Unique sets of cellular genes are
expressed in dually-infected, but not single KSHV-infected PELs
[49]. KSHV LANA potentially activates EBV latent membrane
protein 1 (LMP-1) [50] , but reduces the expression of EBV
EBNA-1 and represses EBV EBNA-2 activation [51]. K-RTA
may potentiate EBV latency via induction of EBV LMP-1 and
uses LMP-1 to curb KSHV lytic replication [52].
Of particular interest in dually infected PELs is the selective
induction of KSHV or EBV lytic replication [12,53]. BC-1 is a
dually infected PEL line. EBV lytic gene expression is activated by
12-O-tetradecanoylphorbol-13-acetate (TPA or phorbol ester).
KSHV lytic gene expression is induced by sodium butyrate
(butyrate or n-butyrate). However, when both TPA and butyrate
are added, KSHV, rather than EBV, is induced into lytic
replication [12,53]. The selective induction of lytic replications
of the two herpesviruses points to the importance of viral factors in
the decision-making processes of PELs.
In this report, we have examined the potential molecular
mechanism behind this selective lytic replication process. We have
found that there is a mutual inhibition between EBV-Z and K-
RTA. Because of their critical roles of the two molecules in
promoting their respective viral lytic replications, our data offer a
possible mechanism for dually-infected cells to keep their
respective viral latencies and for selective switch from latency to
lytic replications.
Results
K-RTA negatively regulates the lytic gene expression of
EBV
Because of the co-presence KSHV and EBV in a same PEL cell
and the selective induction of lytic replication, we suspect that one
or more proteins in KSHV might regulate EBV lytic replication
process. K-RTA is a good candidate because it is immediate early
protein and able to activate an EBV gene [52]. We thus examined
if K-RTA affect the induction of lytic replication of EBV. K-RTA
was transfected into Akata cells, an EBV+/KSHV- BL line, and
the lytic replication of EBV was induced after the treatment with
anti-human-IgG (See Materials and Methods for details). EBV
BMRF1 is a lytic gene and its product is often called the diffuse
component of the EBV-early antigen (EA-D). The essential
function of EA-D in EBV lytic replication has been well
established and using it as indicator of lytic replication has been
widely accepted and appreciated in the field [54–60]. Thus, the
expression of EA-D protein was determined and used as indicator
of EBV lytic replication. As shown in the Fig. 1A, the expression of
EA-D was inhibited upon the expression of K-RTA. Of note
multiple bands of EA-D are often observed during EBV lytic
replication.
In addition, we tested if the same phenomenon can be observed
in another cell line, AGS-Bx1g (EBV+, KSHV2). These cells were
infected by either recombinant adenovirus expressing K-RTA
(AdKRTA) or green fluorescent protein (AdGFP). One day after
the infection, the lytic replication of EBV was examined by the
treatment with TPA. As shown in Fig. 1B, induction of EA-D
protein expression and furthermore the EBV lytic replication was
inhibited by the expression of K-RTA. These data suggested that
K-RTA was a negative regulator of EBV lytic gene expression.
Figure 1. K-RTA inhibits EBV lytic gene expression. A. K-RTA
inhibits the EBV lytic gene expression in Akata cells. Akata (EBV+/KSHV-)
cells were transfected with K-RTA or vector plasmid (5 mg DNA). EBV
lytic replication was induced by anti-human-IgGs a day later (0, 1, 5,
10 mg/ml). Cell lysates were separated on SDS-PAGE, transferred, and
used for western blot analysis. The identity of proteins is as shown. B. K-
RTA inhibits the EBV lytic gene expression in AGS-BX11g cells. AGS-
BX11g (EBV+/KSHV2) cells were infected with recombinant adenovirus
expressing K-RTA or GFP (10 pfu/cell). EBV lytic replication was induced
by TPA a day later. Lysates were used for western blot analysis. The
same membrane was stripped and reprobed with other antibodies. One
representative from three experiments is shown. The identity of
proteins is as shown.
doi:10.1371/journal.pone.0001569.g001
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expression of EBV
It is well established that EBV-Z initiates the lytic replication of
EBV. We further examined that if K-RTA is able to inhibit the
EBV-Z-mediated induction of EBV lytic gene expression.
A serial of cell lines, 293-EBV, BRLF1-KO, and BZLF1-KO,
was used for the experiments. 293-EBV harbors wild type EBV
genome. BRLF1-KO and BZLF1-KO contain the EBV genome
missing BRLF1 (E-RTA) or BZLF1 (EBV-Z) gene respectively
[38]. BRLF1-KO was used primarily because expression of EA-D
was not very sensitive to EBV-Z expression (data not shown). As
shown in the Fig. 2, EBV-Z is able to induce the lytic replication of
EBV as indicated by the induction of EA-D protein. However in
the presence of K-RTA, the expression of EA-D is inhibited
(Fig. 2A). The inhibition is dose-dependent phenomena (Fig. 2B).
Interestingly, EBV-Z and E-RTA can synergistically induce EBV
lytic replication [61–64]. By reducing the expression of EBV-Z
with less plasmid in transfection, we could observe the reported
synergy and K-RTA was a potent inhibitor of the synergistic
activation (Fig. 2C). Essentially the same results can be obtained
from 293-EBV and BZLF1-KO cell lines (data not shown). The
use of more than one cell lines is to ensure the results are not cell-
line dependent. These data suggested that K-RTA inhibited EBV-
Z-mediated lytic gene expression.
K-RTA and EBV-Z physically interact in dually-infected PEL
Next we examined the potential mechanism for K-RTA-
mediated inhibition of EBV lytic replication. Because: 1) EBV-Z
and E-RTA interact functionally and physically [61–64]; 2) K-
RTA and KSHV K8, an EBV-Z homologue, also interact
functionally and physically [22,65,66]; and 3) EBV-Z and KSHV
K8 interact with same cellular genes, such as p53, CBP and C/
EBPa [67–74], we hypothesize EBV-Z and K-RTA interact with
each other physically.
BC1 (EBV+, KSHV+) cells were treated with TPA first to
initiate EBV lytic replication and then treated with butyrate for
KSHV lytic replication. The cells were fixed and stained with both
K-RTA and EBV-Z antibodies. The localization of K-RTA and
EBV-Z was examined under confocal microscope. As shown in the
Fig. 3A, many cells contain both K-RTA and EBV-Z in the same
nuclei (arrows and asters). Some K-RTA and EBV-Z may be co-
localized in the same nuclei (see arrows; yellow color in the Panel
d); suggesting they might be interacting with each other physically.
The high powered versions of the cells are also present at the
bottom. However in some of the cells, both EBV-Z and K-RTA
are expressed in the same cells but the co-localization is not
apparent, possibly due to the fact that one protein is expressed at
much higher levels than the other (see asters). Some cells express
either K-RTA or EBV-Z (see solid squares). Thus EBV-Z and K-
RTA can be co-expressed and co-localized within dually infected
cells.
Next, the co-immunoprecipitation assays were used for
detection of potential physical interactions between K-RTA and
EBV-Z in the induced BC-1 cells. Cell lysates were used for
immunoprecipitation with either K-RTA or EBV-Z antibody. The
immunoprecipitates were then used for western blot analysis with
other specific antibodies. As shown in Fig. 3B, EBV-Z antibody
could bring down K-RTA protein. In addition, the K-RTA
antibody could bring down EBV-Z protein (Fig. 3C). However,
neither normal rabbit serum (NRS) nor normal mouse serum
(NMS) could precipitate EBV-Z or K-RTA protein (Fig. 3B, 3C).
The induced cells express both K-RTA and EBV-Z proteins
(Fig. 3D). These data suggest that EBV-Z and K-RTA interact
with each other in induced BC1 cells in vivo.
Interaction with EBV-Z is required for K-RTA-mediated
inhibition of EBV lytic replication
We suspect that K-RTA may physically interact with EBV-Z
through its leucine heptapeptide repeat region (LR) of K-RTA
[75]. This region is included within the domain of K-RTA
required for interaction with the several cellular proteins such as
K-RBP, RBP-Jk, and C/EBPa [19,23,76,77]. A mutant with the
Figure 2. K-RTA inhibits EBV-Z-mediated EBV lytic gene expression. A. K-RTA inhibits EBV-Z-mediated EBV lytic gene expression. EBV-Z
expression plasmid (0, 0.1, and 0.2 mg) plus K-RTA (0.2 mg) were transfected into BRLF1KO (EBV+/KSHV2) cells in 6-well plate as shown on the top.
Lysates were used for western blot analysis 24 hours later. The same membrane was stripped and reprobed with other antibodies. The identity of
proteins is as shown. B. Dose-dependent inhibition of EBV-Z-mediated lytic gene expression by K-RTA. Fix amount of EBV-Z expression plasmid
(0.1 mg) plus various amounts of K-RTA (0, 0.05, 0.1, 0.2, 0.4 mg) were transfected into BRLF1-KO (EBV+/KSHV2) cells in 6-well plate as shown on the
top. Lysates were used for western blot analysis. Same cell lysates were used. C. K-RTA inhibits the synergistic activation of EA-D. EBV-Z expression
plasmid (0.025 mg), E-RTA (0.1 mg), and K-RTA (0.2 mg) were transfected with different combinations into BRLF1-KO cells as shown on the top. The
same cell lysates were used for western blot analysis. The identity of proteins is as shown.
doi:10.1371/journal.pone.0001569.g002
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mutant protein is localized predominantly in the nucleus as wild
type K-RTA (data not shown). The plasmids expressing EBV-Z,
K-RTA and its mutant were transfected into 293T cells, and the
interaction between EBV-Z and the mutant K-RTA was
examined. While wt K-RTA interacted with EBV-Z properly,
the K-RTA-DLR failed to interact with EBV-Z (Fig. 4B, and 4C).
The expression of these proteins in 293T cells were similar
(Fig. 4D). Thus, the LR region of K-RTA was involved in the
physical interaction with EBV-Z.
Whether the physical interaction is involved in the repression of
EBV-Z-mediated EBV lytic gene expression was examined in
BZLF1-KO (EBV+, KSHV2) cell line. While wt K-RTA was able
to repress EBV lytic replication as expected, the K-RTA-DLR
mutant failed to inhibit the expression of EBV-Z-mediated EA-D
expression (Fig. 4E). Same results can also obtained from 293-EBV
(EBV+, KSHV2) cell line (data not shown). Thus, the interaction
between K-RTA and EBV-Z was required for K-RTA-mediated
inhibition of EBV lytic gene expression.
EBV-Z inhibits the lytic gene expression of KSHV
Next, we examined if EBV-Z affected the induction of lytic gene
expression of KSHV. EBV-Z was transfected into BC3 cells, a
KSHV+/EBV2 PEL line, and the lytic gene expression of KSHV
was examined. Tranfected cells were enriched and split into two
wells: one of which was treated by TPA (see Materials and
Figure 3. K-RTA and EBV-Z interact with each other in dually infected cells. A. Co-localization of K-RTA and EBV-Z in dually infected cells.
BC1 (KSHV+/EBV+) cells were treated with TPA (10 ng/ml) first for one day and then butyrate (0.5 mM) for another day. Cells were fixed and stained
with K-RTA (rabbit) and EBV-Z (mouse) antibodies. Cy5- and Cy2-labeled secondary antibodies were used to distinguish the signals from K-RTA and
EBV-Z, respectively. DAPI was used to stain the nuclei. The colors were artificially mounted to facilitate viewing. Red, K-RTA; green, EBV-Z; blue, nuclei;
(a)K-RTA signal only; (b) EBV-Z signal only; (c) nuclei only; (d) K-RTA, EBV-Z, and nucleus signals are mixed. The pictures of higher power are shown on
the bottom. In Panels B and C, cell extracts from treated BC1 cells were immunoprecipitated (IP) with either anti-EBV-Z or normal mouse serum (Panel
B). Cell lysates were also immunoprecipitated with anti-K-RTA or normal rabbit serum (Panel C). The immunoprecipitates were analyzed by Western
blot using the indicated antibodies. The whole cell lysates of induced BC1 cells were used as positive controls in Panels B and C. In Panel D, whole cell
lysates was used for western blot analyses. The identity of the respective proteins is denoted. n.s., non-specific. Molecular weight (MW) makers are
shown on the left in kilo-Dalton (kDa).
doi:10.1371/journal.pone.0001569.g003
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RTA and KSHV K8, an early KSHV lytic gene, were inhibited
upon the expression of EBV-Z. Due to well-established functions
of K-RTA and K8, the results also suggested that EBV-Z inhibited
lytic replication of KSHV.
Interaction is required for EBV-Z-mediated inhibition of
K-RTA transactivation
We suspect that EBV-Z uses its leucine zipper domain for the
interaction with K-RTA (Fig. 5B). The deletion mutant of leucine
zipper (LZ) domain was made (EBV-Z-LD). In addition, another
point mutation within the domain (EBV-Z-L214D) was also made
because the specific mutation was known to block the dimerization
and functions of EBV-Z [78]. Both mutants are localized in the
nucleus as wild type EBV-Z (data not shown).
The plasmids expressing EBV-Z or its mutants along with K-
RTA were transfected into 293T cells. The interaction between
EBV mutants and K-RTA was examined. Both mutants, EBV-Z-
LD and EBV-Z-L214D failed to interact with K-RTA as shown in
Fig 5C, 5D. The expression of these proteins in 293T cells was
proper (Fig. 5E). Thus, the leucine zipper domain of EBV-Z, and
Leucine 214 in particular, was involved in the interaction with K-
RTA.
Next, we examined if these EBV-Z mutants could affect the
functions of K-RTA. KSHV Pan and K14 promoter reporter
constructs are potently regulated by K-RTA, and the transactiva-
tion was inhibited by the co-expression of EBV-Z. However, the
expression of EBV-Z mutants failed to repress the transactivation
functions of K-RTA (Figs. 5F, 5G). The expression of K-RTA,
EBV-Z, and EBV-Z mutants was confirmed (Fig. 5H). These data
suggested that the interaction between the EBV-Z and K-RTA
was required for the inhibition of K-RTA mediated transactiva-
tion.
Initiation of KSHV lytic gene expression correlated with
the reduction of EBV lytic gene expression
BC-1 (EBV+, KSHV+) is known to induce EBV lytic replication
upon the treatment of TPA. We have tested if we could change the
outcomes of the lytic gene expression by alternation of TPA
dosages.
BC1 cells were treated with different concentration of TPA, and
the lytic gene expression of both EBV and KSHV were analyzed
simultaneously. At low level of TPA treatments, EBV lytic gene
expression was induced as indicated by the expression of EA-D as
well as EBV-Z. However, at higher levels of TPA treatment, EBV
lytic gene expression was turned down. Coincidently, the KSHV
lytic gene expression was initiated as indicated by the expression of
K-RTA and K-8. Thus, TPA could induce either EBV or KSHV
lytic gene expression in BC cells depending on the dosages. More
importantly, the KSHV lytic gene expression apparently correlat-
ed with dampened EBV lytic gene expression. EBV-Z was induced
in a dose dependent manner. At TPA 20 ng/ml, EBV-Z was
expressed at the highest levels, but the EA-D expression was
dropped (Fig 6A; bottom panel). Based on the data in Figures 1
and 2, the expression of K-RTA might block the function of EBV-
Z, which reduced the EA-D levels. Furthermore, the excess K-
Figure 4. Interaction between K-RTA and EBV-Z is required for K-RTA-mediated inhibition. A. Schematic diagram of K-RTA domains and
mutants. The DNA binding domain, leucine heptapeptide repeat region (LR), activation domain, and nuclear localization signal (NLS) are shown. The
drawing is not on scale. In Panels B, C, and D, 293T cells were transfected with of the designated expression plasmids as shown on the top of the
Figure. Cell extracts from these transfected cells were immunoprecipitated with either anti-EBV-Z (Panel B) or anti-K-RTA (Panel C). The
immunoprecipitates were analyzed by Western blot (WB) using the indicated antibodies. In Panel D, whole cell lysate was used for western blot
analyses. The identity of the respective proteins is denoted. E. Interaction between K-RTA and EBV-Z is required for K-RTA-mediated inhibition. 80 ng
of K-RTA or K-RTA-DLR expression plasmids were transfected with various amounts of EBV-Z expression plasmid into BZLF1-KO (EBV+/KSHV2) cells as
shown on the top. Lysates were used for western blot analysis 24 hours later. The same membrane was stripped and reprobed with other antibodies.
The identity of proteins is as shown.
doi:10.1371/journal.pone.0001569.g004
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KSHV K8 expression. It is of note that although different batches
of TPA had different dose response curves, the general trend was
the same even with TPAs from different companies (data not
shown).
Finally, we examined kinetics of the K-RTA RNA expression
under different induction conditions. BC1 cells were treated with
different kinds of chemical inducers. As shown in Fig. 6B, butyrate
or butyrate plus TPA could induce significant K-RTA RNA after
1-2 hours of treatments; however, TPA was able to induce the
similar levels of expression only after 6 hours of the treatment.
Thus comparing to butyrate or TPA plus butyrate, treatment with
TPA induces delayed expression of K-RTA RNA in BC1 cells.
Discussion
The mechanisms of latency and lytic replications of gamma
herpesviruses are extensively studied. The induction processes of
lytic replications are apparently heterogeneous and depend on the
cell, virus, and inducing agent. The co-existance of both EBV and
KSHV in majority of PELs is providing a unique opportunity to
study the interaction between the two viruses and the potential
role in the pathogenesis. The two viruses are apparently able to
interact with each other as well as the host [49–52], and the
presence of both viruses is more potent to promote tumor
formation in rodent model [48].
In this report, we have provided evidence that the critical lytic
replication initiators of KSHV and EBV interact at molecular
levels. First, K-RTA and EBV-Z are co-localized, and the two
proteins physically interact with each other in the same PEL cells
in vivo (Fig. 3). Second, K-RTA inhibits the chemically-induced
EBV lytic gene expression (Fig. 1), and the inhibition may be
related to the fact that K-RTA inhibits EBV-Z mediated lytic
replication process (Fig. 2). EBV-Z and R-RTA physically interact
and synergistically activate EBV lytic gene expression. This
synergistic activation of EBV lytic gene expression is also inhibited
by K-RTA (Fig. 2C), which clear shows the functional difference
between K-RTA and E-RTA. Third, EBV-Z has the similar effect
Figure 5. EBV-Z inhibits KSHV lytic gene expression. A. EBV-Z inhibits KSHV lytic gene expression. BC3 (KSHV+/EBV2) cells were transfected
with CD4 expressing plasmid along with EBV-Z or vector plasmids. The transfected cells were isolated and equally split into two wells: one well of the
cells was treated with TPA for 24 hours. Cell lysates were used for western blot analysis. B. Schematic of EBV-Z functional domains and mutants. The
activation domain, basic region (DNA binding domain), leucine zipper region (LZ), and a region of unknown structure at the C terminus (CT) are
shown. The drawing is not on scale. In Panels C, D, and E, 293T (EBV2/KSHV2) cells were transfected with various expression plasmids as shown on
the top. FLAG-EBV-Z, and its mutants were used. Cell extracts from these transfected cells were immunoprecipitated with either anti-FLAG (for EBV-Z)
(Panel C) or anti-K-RTA (Panel D). The immunoprecipitates were analyzed by Western blot using the indicated antibodies. In Panel E, whole cell lysate
was used for western blot analyses. The identity of the respective proteins is denoted. In Panels F, G, and H, 293T (EBV2/KSHV2) cells were used.
Panel F, KSHV Pan-promoter reporter construct (Pan-luc) and CMV-b-gal expression plasmid were cotransfected with 400 ng of EBV-Z or its mutant
expression plasmids, together with 0, 20, 50 ng of K-RTA expression plasmids respectively as shown on the top. In Panel G, KSHV K14-promoter
reporter construct (K14A-luc) and CMV-b-gal expression plasmid were cotransfected with 100 ng of EBV-Z or its mutant expression plasmids,
together with 0, 10, 20 ng of K-RTA expression plasmids respectively as shown on the top. Luciferase activity was normalized by b -galactosidase
activity. The relative folds of activation of promoter constructs are shown with standard deviations. One representative of three independent
experiments is shown. Panel H, cell lysates from Panel F were used for western blot analysis. The same membrane was stripped and reprobed with
other antibodies. The identity of proteins is as shown.
doi:10.1371/journal.pone.0001569.g005
KSHV and EBV Interactions
PLoS ONE | www.plosone.org 6 February 2008 | Volume 3 | Issue 2 | e1569on KSHV: EBV-Z inhibits the chemically-induced KSHV lytic
gene expression processes (Fig. 5A), and the inhibition is likely due
to that EBV-Z inhibits K-RTA-mediated transactivation (Fig. 5B–
5H). Fourth, the physical interaction between K-RTA and EBV-Z
is apparently required for the mutual inhibition of the two
molecules (Figs. 4 and 5). The leucine heptapeptide repeat region
in K-RTA and leucine zipper region in EBV-Z molecules are
involved in the physical interactions between the two molecules
(Figs. 4 and 5). Fifth, we have shown that initiation of KSHV lytic
gene expression correlated with the reduction of EBV lytic gene
expression (Fig. 6). All these data suggest that K-RTA and EBV-Z
are physically interact and mutually inhibits each others’ functions.
However, we cannot exclude the possibility that K-RTA and
EBV-Z proteins are interacting indirectly through other proteins,
and we are investigating the subject currently. Finally, dually
infected cells can express both K-RTA and EBV-Z in the same
cells under the special induction conditions (Fig. 3A). Of note
under routine induction conditions such as shown in Figure 6,
immunostaining of EBV-Z and K-RTA showed that the majority
of cells were either K-RTA or EBV-Z positive, and only a small
fraction were positive for both (data not shown). All these data
collectively indicate that the physical interaction between the two
proteins is relevant to the control of lytic gene expression in dually
infected cells.
The mechanism of the mutual inhibition is not completely clear
yet. However because both K-RTA and EBV-Z require multi-
merization for their proper functions [75,79], we suspect that the
physical interactions between the two may affect their respective
multimerization process and thus inhibit each others’ function.
There is an interesting phenomenon referred as selective switch
from latency to lytic replication in dually infected cells [12,53].
The mechanisms behind the selective induction of lytic replication
is unknown, but the phenomenon clearly suggests that viral
factor(s) is involved in this selective induction [53]. Based on the
facts that K-RTA and EBV-Z are the critical lytic replication
initiators for KSHV and EBV latencies respectively, and our data
that K-RTA and EBV-Z mutually inhibit each other’s transactiva-
tions, we hypothesize that various chemical treatments and/or
physiological stimuli may trigger differential expression of K-RTA
or EBV-Z. The induced K-RTA and EBV-Z would neutralize
each others’ function through physical interactions. The predom-
inantly-expressed gene product would block the function of
another less-expressed one in dually infected cells. This process
would result in only one critical lytic replication initiator remains
functional in dually-infected PELs. The predominantly expressed
molecule, either K-RTA or EBV-Z, would lead to the selective
lytic replication of one virus in dually-infected PELs. The selective
induction of lytic replication may facilitate the survival of the
winning virus by maximally utilizing cellular resources.
However, KSHV is apparently has an advantage over EBV on
the selective lytic replication processes. First, that the initiation of
KSHV lytic gene expression correlated with the reduction of EBV
lytic gene expression (Fig. 6) suggests that the presence of KSHV
lytic genes is overriding the EBV lytic gene expressions at least in
BC1 cells (Fig. 6A). Second, TPA has been shown to induce lytic
replication of EBV in BC1 cells. We have found that TPA induces
delayed expression of K-RTA, comparing to butyrate or TPA plus
butyrate (Fig. 6B). The delayed induction of K-RTA may provide
an opportunity for lytic replication of EBV in BC1 cells. In
addition, the faster induction of K-RTA by TPA plus butyrate
(Fig. 6B) provides an explanation that TPA and butyrate together
induce KSHV, rather than EBV, lytic replication in BC1 cells.
Third and finally, the induction of expression of the EBV-Z and E-
RTA needs de novo protein synthesis while the induction of K-
RTA of KSHV is not [80]. Therefore with all available data,
KSHV is apparently having an advantage over EBV for the
induction of lytic replication in dually infected PELs.
It is of note that the mutual inhibition of K-RTA and EBV-Z
may be used by both viruses to maintain and/or establish dual
latency in PELs. The dually infected cells are apparently more
Figure 6. Initiation of KSHV lytic gene expression correlated
with the reduction of EBV lytic gene expression. A. TPA induces
either EBV or KSHV lytic replication. BC1 (EBV+/KSHV+) cells were
treated with TPA at indicated dosages shown on the top. Cell lysates
were used for western blot analyses a day later. The same membrane
was stripped and reprobed with other antibodies. The identity of
proteins is as shown. The relative levels of EA-D expression (EA-D/
Tubulin) and EBV-Z (EBV-Z/Tubulin) were obtained by measuring
intensity of EA-D, EBV-Z, and Tubulin using ImageJ 1.37v software
(NIH), and are shown on the bottom panels. One representative from
three independent experiments is shown. B. Kinetics of K-RTA
expression in BC1 cells. BC1 cells were treated with TPA (20 ng/ml),
or butyrate (3 mM), or both. Total RNA were isolated at indicated time
post treatment. The expression of K-RTA and GAPDH RNA was
monitored by RPA with K-RTA and GADPH probes simultaneously.
Specific protections of K-RTA and GAPDH RNAs are indicated. The
relative levels of K-RTA RNA expression (K-RTA/GAPDH) were obtained
by measuring intensity of K-RTA and GAPDH using ImageJ 1.37v
software (NIH), and are shown on the bottom. One representative from
three independent experiments is shown.
doi:10.1371/journal.pone.0001569.g006
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block some spontaneous lytic replications. In addition, the during
primary infection processes to establish the dual latency, both
KSHV and EBV lytic gene expressions are likely to be initiated
[52]. The mutual inhibition of K-RTA and EBV-Z might play a
role for the establishment of dual latency in the same cells in
primary infection.
Our previous data suggest that EBV inhibits the lytic replication
of both KSHV and EBV through another mechanism involved
with EBV latent membrane protein 1 [52]. The general
consequences of EBV-Z or LMP-1-mediated inhibition of KSHV
lytic replication are different: LMP-1 inhibits both EBV and
KSHV lytic replications, while EBV-Z only inhibits KSHV lytic
replication, but initiates EBV lytic replication. The comparative
studies of EBV-Z and LMP-1 for their inhibitory effects on KSHV
lytic replication have not been carried out extensively. However,
the new mechanism identified in this report may reinforce the
point that two viruses would prefer to maintain respective latency
in a dually infected cells. One explanation would be that the lytic
replication of the viruses may lead to the eventual death of the host
cells. Therefore, both viruses may use their interactions to block
potential lytic replication inductions.
In summary, we have addressed how the two viruses interact
with each other in dually infected PELs. Our data may provided a
possible mechanism for maintaining viral latency and for selective
lytic replication in dually infected PELs, i.e., through mutual
inhibition of two critical lytic replication initiators. Of note, the
majority of the current studies on lytic replications of KSHV and
EBV are using KSHV or EBV single-infected cells as model
systems. Therefore, there is a concern about the applicability of
these studies in dually-infected PELs. Our data about putative
interactions between EBV and KSHV would be applicable to the
majority of AIDS-associated PELs and may be relevant to the
pathogenesis of PELs.
Materials and Methods
Plasmids and antibodies
K-RTA, EBV-Z and E-RTA expression plasmids, K14A-luc
and Pan-luc were described previously [18,52]. Flag-EBV-Z
expression plasmid was a gift from Dr. Paul Lieberman. The
mutant plasmids were made with the proper primers and the use
of Quick Change II Site-Directed Mutagenesis Kit (Stratagene).
The oligonucleotides, 59-CCACCGGCAAGGTCACTGGAAG
CCAGTTTGTCATTAGCAAACCC-39 and its complementary
strand were used for deletion of the leucine heptapeptide repeat
(LR) (a.a.# 246-292) in K-RTA (K-RTA-DLR). Primers, 59-
GCCGGGCCAAGTTTAAGCAACTGTGCCCAAGCCTGGA
TGTTGACTCC-39 and its complement strand were used to
delete the leucine zipper region (a.a.# 197-221) of EBV-Z (EBV-
Z-DL). Primes, 59-CAAATCATCTGAAAATGACAGGGATC
GCCTCCTGTTGAAGCAGATG-39 and its complement were
used to change leucine at a.a. #214 of EBV-Z to aspartic acid
(EBV-Z-L214D). CMV-b-galactosidase expression plasmid was
from Clontech. Peptide antibody against K-RTA was described
[52]. K8 antibody was from Dr. Jae Jung. EBV-Z monoclonal
antibody (BZ1; sc-53904) and GAPDH (sc-47724) were purchased
from Santa Cruz Biotechnology. Monoclonal EA-D (EBV-018-
48180) was from Capricorn. E-RTA (11-008) antibody was from
Argene. FLAG (F3165) and Tubulin (T6557) antibodies were
purchased from Sigma. Cy-2-conjugated donkey anti-mouse IgG
(715-225-150) and Cy5-conjugated donkey anti-rabbit IgG (711-
175-152) antibodies were purchased from Jackson ImmunoRe-
search Laboratory.
Cell Culture and Recombinant Adenovirus Infection
Akata (EBV+,KSHV2) is an BL line. BC1 (EBV+,KSHV+)a n d
BC3 (EBV2, KSHV+) are PEL lines [81,82]. These cells were
maintained in RPMI1640 plus 10% FBS. 293T (EBV2,KSHV2)
is human fibroblast line. 293EBV (EBV+,K S H V 2) is a 293
fibroblast derived cell line with wild type EBV genome[38].
BRLF1KO and BZLF1KO were also 293 fibroblast derived cell
lines with BRLF1 or BZLF1 deletion in their respective EBV
genomes [38]. These three lines were maintained in DMEM plus
10% FBS plus 0.5 mg/ml hygromycin. AGS-BX11g is an epithelial
cell line with EBV genome and was maintained in DMEM plus
10% FBS plus 0.5 mg/ml G418 [83]. The recombinant adenovirus
for green fluorescence protein (GFP) (AdGFP) and K-RTA
(AdRTA) were a gift from Dr. Byrd Quinlivan [84]. The
recombinant adenoviruses were titered in 293 cells. AGS-BX11g
cells were infected by recombinant viruses at a multiplicity of
infection (MOI) of 10 (calculated from PFU). One day later, cells
were then treated with TPA for induction of EBV lytic replication.
Induction of lytic replication
12-O-tetradecanoylphorbol-13-acetate (TPA; from Sigma or
Aldrich) was used to treat BC3 (5–10 ng/ml), BC1 (1–40 ng/ml),
and AGS-BX11g (0.5–2 ng/ml) for induction of lytic replication.
Sodium butyrate was also used for induction of lytic replications.
Goat anti-human immunoglobulin G (IgG) (Sigma; Cat# I-9384)
was used to activate EBV lytic replication in Akata cells. For
immunostainingand co-immunoprecipitationexperimentsinFig.3,
BC1 cells were treated with 10 ng/ml TPA overnight, and then
treated with butyrate (0.5 mM). The cells were collected a day later
for immunostaining and immunoprecipitation experiments.
Transient Transfection, Isolation of Transfected cells, and
Reporter Assays
Effectene (Qiagen) was used for the transfection of 293EBV,
BRLF1-KO, BZLF1KO and 293T cells. Transfection of Akata
cells were achieved by using Amaxa Nucleofector Device. Briefly,
5 mg of plasmids were transfected into 2610
6 cells in 100 ml
solution V using program G016. Six hours later, the transfected
cells were treated with anti-human-IgG. Transfection efficiency
was about 70%. Electroporation (320V; 925 mF) was used for
transfection of BC3 cells and the selection of transfected cells was
essentially the same as described previously [85–87]. CD4 and
other expression plasmids were transfected into BC3 cells. One
day after the transfection, the cells were used for isolation of CD4-
positive cells with the use of Dynabeads CD4 (Dynal Inc). The
enriched cells were detached from the Dynabeads CD4 by
incubation for 45–60 minutes at room temperature with 10 mlo f
DETACHaBEAD (Dynal). The detached beads were removed by
using a magnet separation device. The released cells were washed
2–3 times with 500 ml RPMI 1640 plus 10% FBS, and
resuspended in RPMI 1640 plus 10% FBS at 5610
5 cells/ml.
Cells were split into two wells and recovered for 2–6 hours: TPA
(5 ng/ml) were added into one well. The treated cells were
collected one day later. The luciferase assays were performed using
the assay kit from Promega according to manufacturer’s
recommendation.
Western Blot Analysis, RNA extraction, and RNase
Protection Assays (RPA)
Standard western blot analysis was performed as described [88].
Total RNA was isolated from cells using the RNeasy Total RNA
Isolation Kit (Qiagen). RPA was performed with total RNA using
the RNase Protection Assay Kit II (Ambion) as described [87]. The
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RTA was made by PCR of the K-RTA region (BC1 coordinates:
72601-72900) followed by cloning into pcDNA3 vector.
Co-immunoprecipitation (Co-IP)
BC-1 cellsweretreatedwith10 ngTPA permlfor24 h,andwith
0.5 mM sodium butyrate for another 24 h. 293T cells grown in 10-
cm plates were transfected with the designated plasmids, and cells
were ready for experiments 24 hours later. These cells were washed
with PBS and lysed at 4uC for 30 min in EBC buffer (50 mM Tris-
HCl, pH7.5, 120 mM NaCl, 0.5% NP-40) supplemented with
protease inhibitor cocktail tablet (Roche) with gentle rotation. The
cell lysates were centrifuged at 16,1006g for 15 min, and the
supernatants were recovered. For coimmunoprecipitation, lysates
were pre-cleared with normal rabbit or mouse IgG with 20 ml
Protein G Sepharose. Specific antibodies and Protein G Sepharose
(GE Healthcare) at 4uC for 1hour or overnight. The beads were
washed three times with EBC buffer, boiled in SDS loading buffer,
and subsequent Western blot were essentially the same as described.
Immunochemical analysis
The TPA and butyrate treated BC1 cells were centrifuged and
washed with phosphate-buffered saline solution (PBS), and fixed
with 4% paraformaldehyde for 15 minutes. The cells were
permeabilized with 100% cold methanol for 5 minutes. After
washing with PBS, the cells were blocked with PBST including 1%
BSA for 30 minutes. The cells were incubated with antibodies
against EBV-Z (1:50 dilution) and K-RTA (1:50 dilution) for one
hour. Following three washing with PBST, the cells were
incubated for one hour with Cy-2 conjugated secondary antibodies
against mouse IgG (1:60) and Cy5 -conjugated secondary
antibodies against rabbit IgG (1:60). Finally, DAPI was used for
nuclei staining and the cells were mounted (Gel Mount Aqueous
Mounting Medium, Sigma) in the poly-prep slides (Sigma) for
analysis with confocal microscopy (Olympus FV500) in the
Microscopy Core facility at the University of Nebraska-Lincoln.
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